Recently, the Nevalainen group identified and validated a small molecule inhibitor which targets the Stat5a/b SH2 domain in both PC and CML, malignancies known to be driven by Stat5a/b signaling [211]. Here, STAT5A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.